<DOC>
	<DOCNO>NCT00047502</DOCNO>
	<brief_summary>The purpose study investigate effect lonafarnib ( SCH66336 ) combination Gleevec treatment CML .</brief_summary>
	<brief_title>Study Lonafarnib Gleevec Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>Existing pre-clinical clinical data suggest SCH66336 , farnesyl transferase inhibitor , exhibit significant activity CML cell , fact may synergistic activity combination imatinib mesylate . Thus , objective study ( 1 ) determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) lonafarnib ( SCH66336 ) , farnesyl transferase inhibitor , combination imatinib mesylate ( Gleevec ) patient chronic phase , accelerated phase , blast crisis CML ; ( 2 ) ass pharmacokinetics combination lonafarnib Gleevec patient ; ( 3 ) ass preliminary way biologic activity combination lonafarnib Gleevec patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patients Philadelphia chromosome ( ph ) positive CML follow category : 1 . Chronic phase patient must fail therapy Gleevec . Failure define : ( ) Patients achieve lose hematologic response 3 month start therapy Gleevec , ( ii ) Patients achieve lose cytogenetic response 6 month therapy Gleevec , ( iii ) Patients achieve lost major cytogenetic response 12 month therapy Gleevec . 2 . Patients accelerated phase , define presence follow feature : ( ) blast peripheral blood ( PB ) bone marrow ( BM ) &gt; /= 15 % ( &lt; 30 % ) , ( ii ) blast + promyelocytes PB BM &gt; /= 30 % , ( iii ) basophils PB BM &gt; /= 20 % , ( iv ) platelets &lt; 100 x 10e9/L unrelated therapy , ( v ) clonal evolution . 3 . Patients blast phase , define presence &gt; /= 30 % blast peripheral blood and/or bone marrow , presence extramedullary disease . 2 ) Patients accelerate blastic phase eligible whether receive and/or fail Gleevec . 3 ) Age &gt; /= 16 year . 4 ) Patients must sign informed consent indicate aware investigational nature study keep eith policy hospital . The acceptable consent form attach end protocol . 5 ) Performance status &lt; /= 2 Zubrod scale . 6 ) Patients must adequate hepatic function ( bilirubin &lt; /= 2.0 mg/dl ) renal function ( creatinine &lt; /= 2 mg/dl ) . 7 ) Exclusion criterion : 1 . Patients QTc &gt; 500 msec . 2 . Patients severe heart disease ( cardiac class III IV ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>